Other 🇺🇸, United States
MannKind develops inhaled drug-delivery technology, including its Technosphere platform. Its collaboration with Rose Pharma covers development and manufacturing support for the investigational ROSE-010 program through Phase 1b. This profile follows its partnerships and the commercial development of its delivery technology in the wider metabolic-health market.
Market cap not yet added.
Last 12 months
Last 12 months
Rose Pharma will use MannKind’s inhalation technology to develop an inhaled version of an experimental weight-loss drug. MannKind receives a stake in Rose Pharma and a share of potential future sales.
MannKindGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
